Implantable Contact Lens (ICL)
MidWest Eye Center is committed to implementing the latest and greatest in visual corrective surgery and is pleased to offer the EVO Visian Implantable Contact Lens (EVO ICL), one of the newest FDA approved eyecare technologies.
What Is EVO ICL?
EVO Visian® ICL (as also known as “EVO”) is an evolution in visual correction surgery, providing patients with freedom from the inconvenience, discomfort, and expense that often comes from contact lenses and glasses.
EVO ICL is an implantable lens positioned just below the surface of the eye to correct nearsightedness (both myopia and myopia with astigmatism). The procedure was designed to be even more comfortable for the patient than earlier versions of the Visian ICL and a faster, more efficient procedure for surgeons than traditional laser surgeries. The collamer base of the lens material is 100 percent biocompatible and was created to function in harmony with your body’s chemistry. Thanks to the EVO ICL procedure, people have been granted the flexibility to live more active lifestyles and enjoy an improved quality of life.
EVO ICL Benefits
The procedure corrects a wide range of eye prescriptions quickly and effectively, delivering excellent night vision and even built-in UV protection. It is designed to provide permanent vision correction, although it is both removable and replaceable when needed. EVO is an ideal option for patients who don’t prefer glasses or contact lenses and are not candidates for laser eye surgery.
The recovery time for the EVO ICL is very quick, comfortable, and maybe as little as a day, due to the small size of the incision made during the procedure. The incision needed to implant the foldable EVO ICL is located on the far edge of the cornea, where there is little danger of it interfering with vision.
Visian ICL has been approved in Europe since 1997 and in the U.S. since 2005. In 2018, the addition of the Visian Toric ICL expanded the range of vision which be treated directly with the lens to include up to 4 diopters of astigmatism. Higher degrees of astigmatism can even be treated by combining the ICL with other procedures. In 2019, one million Visian ICLs were implanted to date, with studies showing a 99 percent patient satisfaction rate. Demand for the EVO procedure has more than doubled since 2018 amongst patients, becoming one of the premier solutions for refractive vision correction throughout the world.
EVO ICL: Who Is A Candidate?
Every patient has unique vision correction and eye care needs which is why it’s important to schedule an online or in-person consultation with an eye doctor at MidWest Eye Center to make an informed decision about the procedure.
You may be an excellent candidate if you:
- Are between the ages of 21 and 45
- Are nearsighted, a.k.a. myopic (-3 D up to -20 D)
- Optionally have astigmatism (up to -4 D)
EVO ICL can be used for patients suffering from dry eye, with thin or abnormal corneas, and in many other situations which might preclude LASIK.